Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2024

Open Access 01-12-2024 | Ticagrelor | Review

Progress in the clinical effects and adverse reactions of ticagrelor

Authors: Peng Wei, Xiaoqing Wang, Qiang Fu, Bangming Cao

Published in: Thrombosis Journal | Issue 1/2024

Login to get access

Abstract

Background

Ticagrelor is a novel receptor antagonist that selectively binds to the P2Y12 receptor, thereby inhibiting adenosine diphosphate (ADP)-mediated platelet aggregation. Compared to clopidogrel, ticagrelor has the advantages of a fast onset, potent effects, and a reversible platelet inhibition function, which make this drug clinically suitable for treating acute coronary syndrome (ACS), especially acute ST-segment elevation myocardial infarction (STEMI).

Objective

This review was performed to determine the basic characteristics, clinical effects, and adverse reactions of ticagrelor.

Methods

Relevant trials and reports were obtained from the MEDLINE, Embase, and Cochrane Library databases.

Results

Ticagrelor is rapidly absorbed by the body after oral administration, exhibits inherent activity without requiring metabolic activation, and binds reversibly to the P2Y12 receptor. Ticagrelor has been recommended in ACS treatment guidelines worldwide due to its advantageous pharmacological properties and significant clinical benefits. Ticagrelor inhibits platelet aggregation, inhibits inflammatory response, enhances adenosine function, and has cardioprotective effects. However, ticagrelor also causes adverse reactions such as bleeding tendency, dyspnea, ventricular pause, gout, kidney damage, and thrombotic thrombocytopenic purpura in clinical treatment. Therefore, it is necessary to pay attention to risk assessments when using ticagrelor.

Conclusion

Ticagrelor is a promising drug for the effective treatment of ACS. When using ticagrelor, individualized treatment should be provided based on the specific conditions of the patients to avoid serious adverse events.
Literature
1.
Amsterdam EA, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2014;64(24):2645–87.CrossRef
2.
Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259–74.PubMedCrossRef
3.
Li Y, Landqvist C, Grimm SW. Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets. Drug Metab Dispos. 2011;39(9):1555–67.PubMedCrossRef
4.
Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost. 2011;105(Suppl 1):S75–81.PubMed
5.
6.
Sandinge AS, et al. Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452. PLoS ONE. 2018;13(7):e0201202.PubMedPubMedCentralCrossRef
7.
Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52(9):1388–98.PubMedCrossRef
8.
Jeong KH, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with Kidney Failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015;65(6):916–24.PubMedCrossRef
9.
Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2(1):30–9.PubMedPubMedCentralCrossRef
10.
Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73(15):1681–709.
11.
Kuczyńska K, Boncler M. Emerging role of Fentanyl in Antiplatelet Therapy. J Cardiovasc Pharmacol. 2020;76(3):267–75.PubMed
12.
Franchi F, et al. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet effects in Coronary Artery Disease patients treated with Morphine. JACC: Cardiovasc Interventions. 2019;12(16):1538–49.
13.
Iglesias JF, Valgimigli M, Carbone F, Lauriers N, Masci PG, Degrauwe S. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: full results of the PERSEUS randomized trial. Cardiol J. 2022;29(4):591–600.
14.
Gurbel PA, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery Disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–85.PubMedCrossRef
15.
JJ VANG, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556–65.CrossRef
16.
Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016;128(23):2717–28.PubMedPubMedCentralCrossRef
17.
Astrand M, et al. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery Disease and prior Myocardial Infarction patients. Br J Clin Pharmacol. 2019;85(2):413–21.PubMedCrossRef
18.
Venetsanos D, et al. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res. 2017;149:88–94.PubMedCrossRef
19.
Marian MJ, et al. Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-negative Acute Coronary Syndrome patients undergoing percutaneous coronary intervention: a Randomized Clinical Trial. J Am Heart Assoc. 2019;8(23):e012844.PubMedPubMedCentralCrossRef
20.
Franchi F, et al. Platelet inhibition with Cangrelor and Crushed Ticagrelor in patients with ST-Segment-Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention. Circulation. 2019;139(14):1661–70.PubMedCrossRef
21.
Hochholzer W, Neumann FJ. [The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation] Dtsch Med Wochenschr, 2016. 141(11): p. 782-5.
22.
Anderson JL et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol, 2013. 61(23): p. e179-347.
23.
Franchi F, et al. Impact of escalating loading dose regimens of Ticagrelor in patients with ST-Segment Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention: results of a prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. Volume 8. JACC: Cardiovascular Interventions; 2015. pp. 1457–67. 11.
24.
Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.PubMedCrossRef
25.
Wang Q, Lin W. Application of ticagrelor in the treatment of acute coronary syndrome. Shandong Med. 2015;55(7):77–9.
26.
Liu HL, et al. Design and rationale of the APELOT Trial: a randomized, Open-Label, Multicenter, Phase IV Study to evaluate the Antiplatelet Effect of different loading dose of Ticagrelor in patients with Non-ST Acute Coronary Syndrome undergoing percutaneous coronary intervention. Med (Baltim). 2016;95(22):e3756.CrossRef
27.
James S, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.PubMedCrossRef
28.
Cannon CP, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–93.PubMedCrossRef
29.
Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass Surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol. 2011;57(6):672–84.PubMedCrossRef
30.
Gurbel PA, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–99.PubMedCrossRef
31.
Biswas M, Kali SK. Association of CYP2C19 loss-of-function alleles with major adverse Cardiovascular events of Clopidogrel in stable coronary artery Disease patients undergoing percutaneous coronary intervention: Meta-analysis. Cardiovasc Drugs Ther. 2021;35(6):1147–59.PubMedCrossRef
32.
Biswas M, et al. Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Platelets. 2021;32(5):591–600.PubMedCrossRef
33.
Stimpfle F, et al. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thromb Res. 2014;134(1):105–10.PubMedCrossRef
34.
Biswas M, et al. Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery Disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(12):1605–16.PubMedCrossRef
35.
Holmberg MT, et al. CYP3A4*22 impairs the elimination of Ticagrelor, but has no significant effect on the Bioactivation of Clopidogrel or Prasugrel. Volume 105. Clinical Pharmacology & Therapeutics; 2019. pp. 448–57. 2.
36.
Liu S, et al. Effect of CYP3A4(*)1G and CYP3A5(*)3 polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in healthy Chinese subjects. Front Pharmacol. 2017;8:176.PubMedPubMedCentral
37.
Badrnya S, et al. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb Haemost. 2012;108(4):719–29.PubMedCrossRef
38.
39.
Liu O, et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic Aneurysm progression. PLoS ONE. 2012;7(12):e51707.PubMedPubMedCentralCrossRef
40.
Solheim S, et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary Heart Disease. Thromb Haemost. 2006;96(5):660–4.PubMed
41.
Chen YG, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J (Engl). 2006;119(1):32–6.PubMedCrossRef
42.
Liu S, et al. Effect of CYP3A4(∗)1G and CYP3A5(∗)3 polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in healthy Chinese subjects. Front Pharmacol. 2017;8:176.PubMedPubMedCentral
43.
Gasecka A, et al. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Cardiol J. 2019;26(6):782–9.PubMedCrossRef
44.
Nylander S, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost. 2013;11(10):1867–76.PubMedCrossRef
45.
van Giezen JJ, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17(2):164–72.PubMedCrossRef
46.
Wittfeldt A, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61(7):723–7.PubMedCrossRef
47.
Alexopoulos D, et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv. 2013;6(3):277–83.PubMedCrossRef
48.
Wang K, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine Coronary Thrombosis model. Thromb Haemost. 2010;104(3):609–17.PubMed
49.
Birnbaum Y, Ling S, Nanhwan, MK, Kodakandla M, Ye Y. Ticagrelor, but not clopidogrel, protects the heart and limits myocardial infarct size. J Am Coll Cardiol. 2014;63(12):A22.
50.
Shabaiek A, et al. Role of Cardiac myocytes Heart fatty acid binding protein depletion (H-FABP) in early Myocardial Infarction in Human Heart (autopsy study). Open Access Maced J Med Sci. 2016;4(1):17–21.PubMedPubMedCentralCrossRef
51.
Zhang YR, Xue ZK, Chen KY. Loading doses of ticagrelor versus clopidogrel in preventing periprocedural Myocardial Infarction in Asian patients with acute coronary syndrome. 2021. 36(2): p. 122–9.
52.
53.
Ohman J, et al. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun. 2012;418(4):754–8.PubMedCrossRef
54.
Unverdorben M, et al. Dyspnea related to reversibly-binding P2Y12 inhibitors: a review of the pathophysiology, clinical presentation and diagnostics. Int J Cardiol. 2016;202:167–73.PubMedCrossRef
55.
Mustafa SJ, et al. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol. 2009;193:161–88.CrossRef
56.
Crisci M, et al. Improving adherence to Ticagrelor in patients after Acute Coronary Syndrome: results from the PROGRESS trial. Curr Vasc Pharmacol. 2020;18(3):294–301.PubMedCrossRef
57.
Cesaro A, et al. Low-dose Ticagrelor in patients with high ischemic risk and previous Myocardial Infarction: a multicenter prospective real-world Observational Study. J Cardiovasc Pharmacol. 2020;76(2):173–80.PubMedCrossRef
58.
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038–47.
59.
Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, et al. Ticagrelor versus Clopidogrel in patients With STEMI treated With fibrinolysis: TREAT Trial. J Am Coll Cardiol. 2019;73(22):2819–2828.
60.
Galimzhanov AM, Azizov BS. Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: a systematic review and meta-analysis of observational studies. Indian Heart J. 2019;71(1):15–24.PubMedPubMedCentralCrossRef
61.
Lun R, et al. Comparison of Ticagrelor vs Clopidogrel in Addition to aspirin in patients with minor ischemic Stroke and transient ischemic Attack: a Network Meta-analysis. JAMA Neurol. 2022;79(2):141–8.PubMedCrossRef
62.
Andreou I, et al. Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a systematic review and Meta-analysis. Cardiovasc Drugs Ther. 2018;32(3):287–94.PubMedCrossRef
63.
64.
65.
Mehran R et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med, 2019.
66.
Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med. 2015;372(2):196–7.
67.
Martin AC, et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol. 2016;33(5):361–7.PubMedCrossRef
68.
Almquist J, et al. Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics Syst Pharmacol. 2016;5(6):313–23.PubMedPubMedCentralCrossRef
69.
Bhatt DL, et al. Antibody-based ticagrelor reversal Agent in healthy volunteers. N Engl J Med. 2019;380(19):1825–33.PubMedCrossRef
70.
Qaderdan K, et al. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: optimization of antiplatelet treatment in patients 70 years and older–rationale and design of the POPular AGE study. Am Heart J. 2015;170(5):981–985e1.PubMedCrossRef
71.
Caldeira D, Pinto FJ, Ferreira JJ. Dyspnea and reversibility profile of P2Y(1)(2) antagonists: systematic review of new antiplatelet Drugs. Am J Cardiovasc Drugs. 2014;14(4):303–11.PubMedCrossRef
72.
Mehran R, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382(9906):1714–22.PubMedCrossRef
73.
Gaubert M, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol. 2014;173(1):120–1.PubMedCrossRef
74.
Armstrong D, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19(2):209–19.PubMedCrossRef
75.
Lindholm D, et al. Design and rationale of TROCADERO: a TRial of caffeine to Alleviate DyspnEa related to ticagrelOr. Am Heart J. 2015;170(3):465–70.PubMedCrossRef
76.
Butler K, Maya J, Teng R. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and Asthma or Chronic Obstructive Pulmonary Disease patients. Curr Med Res Opin. 2013;29(5):569–77.PubMedCrossRef
77.
Cannon CP, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50(19):1844–51.PubMedCrossRef
78.
79.
Nicol M, et al. Side effects of ticagrelor: sinus node dysfunction with ventricular pause. Int J Cardiol. 2015;191:56–7.PubMedCrossRef
80.
Scirica BM, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (platelet inhibition and patient outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011;57(19):1908–16.PubMedCrossRef
81.
Baker NC, Nadour W, Friehling M. Clinically significant ticagrelor induced conduction abnormalities following percutaneous coronary intervention. Int J Cardiol. 2016;214:21–2.PubMedCrossRef
82.
Zhang N, et al. Another side effect of ticagrelor: atrial fibrillation. Int J Cardiol. 2016;212:242–4.PubMedCrossRef
83.
Goldberg A, et al. Life-threatening complete atrioventricular block associated with ticagrelor therapy. Int J Cardiol. 2015;182:379–80.PubMedCrossRef
84.
Bonaca MP, et al. Long-term use of ticagrelor in patients with prior Myocardial Infarction. N Engl J Med. 2015;372(19):1791–800.PubMedCrossRef
85.
Butler K, Teng R. Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. Clin Pharmacol Ther. 2012;91(2):264–71.PubMedCrossRef
86.
Enomoto A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447–52.PubMedCrossRef
87.
Ichida K, et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 2003;63(1):143–55.PubMedCrossRef
88.
Cattaneo M, Faioni EM. Why does Ticagrelor induce dyspnea? Thromb Haemost. 2012;108(6):1031–6.PubMed
89.
Zhang N, et al. Ticagrelor-related gout: an underestimated side effect. Int J Cardiol. 2015;192:11–3.PubMedCrossRef
90.
Htun P, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 2011;22(4):627–33.PubMedPubMedCentralCrossRef
91.
Morel O, et al. Cardiovascular mortality in chronic Kidney Disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57(4):399–408.PubMedCrossRef
92.
Washam JB, et al. Pharmacotherapy in chronic Kidney Disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131(12):1123–49.PubMedCrossRef
93.
van Vuren AJ, de Jong B, Bootsma HP, Van der Veen MJ, Feith GW. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis. Neth J Med. 2015;73(3):136–8.
94.
DiNicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clin Cardiol. 2012;35(11):647–8.PubMedPubMedCentralCrossRef
95.
Jacob S, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on adverse reactions (SONAR). Semin Thromb Hemost. 2012;38(8):845–53.PubMedPubMedCentralCrossRef
96.
Bennett CL, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342(24):1773–7.PubMedCrossRef
97.
98.
Wang X, et al. Ticagrelor-induced thrombotic thrombocytopenic purpura: a case report and review of the literature. Med (Baltim). 2018;97(26):e11206.CrossRef
99.
Welsh RC, et al. Outcomes among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction patients who underwent primary percutaneous coronary intervention from the TOTAL trial. Can J Cardiol. 2019;35(10):1377–85.PubMedCrossRef
Metadata
Title
Progress in the clinical effects and adverse reactions of ticagrelor
Authors
Peng Wei
Xiaoqing Wang
Qiang Fu
Bangming Cao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2024
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-023-00559-3

Other articles of this Issue 1/2024

Thrombosis Journal 1/2024 Go to the issue

Research

Association of inherited thrombophilia mutations and their combinations among palestinian women with unexplained recurrent miscarriage

Review

C-type lectin-like receptor 2: roles and drug target

Research

Reduced mortality associated with pulmonary embolism response team consultation for intermediate and high-risk pulmonary embolism: a retrospective cohort study

Research

Factors influencing DVT formation in sepsis

Research

A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor IX gene

Research

Renal damage and old age: risk factors for thrombosis in patients with ANCA-associated vasculitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits